Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6264005 | 0.98 | CYP4F2 (0.50) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| SCHEMBL26016142 | 0.83 | CYP4F2 (0.35) | CYP4F2CYP4A11LMNAHSD17B10KDM4E | |
| SCHEMBL8212091 | 0.83 | CYP4F2 (0.46) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| SCHEMBL22519700 | 0.82 | CYP4F2 (0.58) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| Hydrochloric Acid SCHEMBL28096965 | 0.81 | SOAT1 (0.52) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| SCHEMBL22922997 | 0.80 | CYP4F2 (0.35) | CYP4F2CYP4A11ALOX15ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL4768682 | 0.80 | CYP4F2 (0.56) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| SCHEMBL2021436 | 0.80 | CYP4F2 (0.67) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| SCHEMBL18363110 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11ALOX15ALDH1A1PKM | |
| SCHEMBL130722 | 0.80 | CYP4F2 (0.55) | CYP4F2CYP4A11ALOX15ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | claimed |
| CN-109232613-A | For treating and preventing the condensed heteroaryl dihydro-pyrimidin of hepatitis b virus infected new 6- | 豪夫迈·罗氏有限公司 | 2019-01-18 | — | — | CN | claimed |
| EP-3946460-B1 | IMPROVED CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260007768-A1 | CONJUGATION LINKERS | PROLYNX LLC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4608810-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12364771-B2 | Conjugation linkers | PROLYNX LLC (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4561575-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119970617-A | Improved coupling joint | 普罗林科斯有限责任公司 | 2025-05-13 | — | — | CN | disclosed |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2025-04-10 | — | — | US | disclosed |
| EP-4384520-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | Uppthera, Inc. (KR) | 2024-06-19 | — | — | EP | disclosed |
| CN-118184650-A | 6- (1H-pyrrolo [2,3-b ] pyridin-3-yl) quinazoline-4-amine derivative, and preparation method and application thereof | 中国人民解放军北部战区总医院 | 2024-06-14 | — | — | CN | disclosed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5506240-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| EP-0678503-A1 | Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities | CIBA-GEIGY AG (CH) | 1995-10-25 | — | — | EP | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0528762-A1 | N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists | CIBA-GEIGY AG (CH) | 1993-02-24 | — | — | EP | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |
| EP-0014997-B1 | 4-ARYLOXY- AND 4-ARYLTHIO-3-PHENYLPIPERIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION OF SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007768-A1 | CONJUGATION LINKERS | OGFR, SLC43A1, ILK | CYP4F2 1044/4885CYP4A11 1010/4885ALOX15 3551/4885 |
| US-20250114460-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CYP4F2 4659/4885CYP4A11 4119/4885ALOX15 3855/4885 |
| US-12364771-B2 | Conjugation linkers | DNPEP, FGB, VIP | CYP4F2 3234/4885CYP4A11 4429/4885ALOX15 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.